Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Efient AGs Widen Labels to Close Indication Gap
June 18, 2026
- AZ, Kyoto Ink Pact to Promote NCD Prevention, Early Detection
June 18, 2026
- Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
June 17, 2026
- Adstiladrin Expected to Ease Patient Burden in Bladder Cancer: Experts
June 17, 2026
- Astellas CEO’s Pay Rises to 733 Million Yen in FY2025: Securities Report
June 17, 2026
- Torii Starts PIII Trial of Cantharidin for Common Warts
June 17, 2026
- Ono CEO’s Pay Climbs to 260 Million Yen
June 16, 2026
- Six Eisai Executives Took Home Over 100 Million Yen in FY2025
June 16, 2026
- Hisamitsu to Raise Prices on Salonpas, Other OTC Products
June 16, 2026
- Eisai to Invest £48 Million to Build Cold-Chain Capability in UK
June 16, 2026
- Susmed Bags 240 Million Yen Milestone for Tinnitus App
June 16, 2026
- Vanflyta Wins China Nod for Frontline AML
June 16, 2026
- Otsuka Closes US$700 Million Transcend Buyout
June 16, 2026
- Takeda’s Zasocitinib Beats Sotyktu in PIII Psoriasis Trial
June 15, 2026
- Rakuten Medical CEO-Elect Reaffirms 2028 US Filing Plan for Akalux
June 15, 2026
- Heartseed Starts Japan PI/II of Catheter-Delivered iPSC Cardiomyocyte Therapy
June 15, 2026
- Lilly Breaks Ground on New Building at Kobe Plant
June 15, 2026
- Shionogi Invests in Reproductive Medicine Startup Dioseve
June 15, 2026
- Chugai Files Tecentriq for Esophageal Cancer
June 15, 2026
- AbbVie Japan Files Rinvoq for Takayasu Arteritis
June 15, 2026
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…